Repligen corp stock.
Repligen Corp’s ( RGEN) price is currently up 0.21% so far this month. During the month of March, Repligen Corp’s stock price has reached a high of $189.87 and a low of $171.57. Over the last year, Repligen Corp has hit prices as high as $262.26 and as low as $137.21. Year to date, Repligen Corp’s stock is down 34.02%.
The number of shares of the Company's common stock, $0.01 par value per share ("Common Stock"), entitled to vote at the Annual Meeting was 55,429,107. The number of shares of Common Stock present or represented by valid proxy at the Annual Meeting was 51,525,212, representing 92.96% of the total number of shares of Common …What is Repligen Corp (RGEN)'s stock price today? The current price of RGEN is $153.28. The 52 week high of RGEN is $212.17 and 52 week low is $110.45. When is next earnings date of Repligen Corp (RGEN)? The next earnings date of Repligen Corp (RGEN) is …45.97M. 305.46%. Get the latest Repligen Corp (RGEN) real-time quote, historical performance, charts, and other financial information to help you make more informed …Currently, there are 55.54 million shares of Repligen Corp stock available for purchase. Repligen Corp’s price-earnings (P/E) ratio is currently at 49.4, which is high compared to the Medical Equipment, Supplies & Distribution industry median of 33.1. The price-earnings ratio gauges market expectation of future performance by relating a stock ...
The stock price of Repligen (NASDAQ: RGEN), a U.S.-based life sciences company involved in production of materials used in the manufacture of biological drugs, …
View the latest Repligen Corp. (RGEN) stock price, news, historical charts, analyst ratings and financial information from WSJ.
Stock analysis for Repligen Corp (RGEN:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Sep 29, 2023 · Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 15.77% in the past year. Currently, Repligen Corp’s price-earnings ratio is 65.8. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%. Investors. These pages provide visibility to Repligen news, SEC filings, financial and other information that may factor into an investment decision. We welcome your questions or comments. [email protected] the last quarter, Repligen (NASDAQ:RGEN) has observed the following analyst ratings: According to 7 analyst offering 12-month price targets in the last …
Phone 1 781 250-0111. Industry Biotechnology. Sector Health Care/Life Sciences. Fiscal Year-end 12/2023. Revenue €801.54M. Net Income €185.96M. 2022 Sales Growth 19.54%. Employees 2,025.
Repligen Corp (RGEN) Stock Shows Promising Performance on September 12, 2023: Analysts Predict 22.75% Increase. On September 12, 2023, Repligen Corp (RGEN) stock showed promising performances based on the information provided by CNN Money. The 13 analysts offering 12-month price forecasts for RGEN have a median …
First quarter 2021 adjusted EPS increased to $0.68 per fully diluted share, compared to $0.32 in the 2020 period, an increase of $0.37, or 116%. Cash and cash equivalents, which are GAAP metrics ...Oct 13, 2023 · The Growth Grade Winner: Repligen Corp. As you can clearly see from the Growth Grade breakdown above, Repligen Corp has a more attractive growth grade than Medtronic PLC. For investors who focus solely on how a company is growing relative to other companies in the same industry, Repligen Corp could be a good stock to add to their portfolio. Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. It operates through the North America. Europe, and Asia Pacific Region or Other geographical segments. 1 thg 11, 2023 ... While Repligen Corporation ( NASDAQ:RGEN ) might not be the most widely known stock at the moment, it saw a...Oct 18, 2023 · Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 30.36% in the past year. Currently, Repligen Corp’s price-earnings ratio is 58.9. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%. 6 hours ago · According to 7 analyst offering 12-month price targets in the last 3 months, Repligen has an average price target of $186.71 with a high of $210.00 and a low of $165.00. Stock Price Forecast The 13 analysts offering 12-month price forecasts for Repligen Corp have a median target of 170.00, with a high estimate of 210.00 and a low estimate of 148.00.
Nov 13, 2023 · Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 15.54% in the past year. Currently, Repligen Corp’s price-earnings ratio is 72.6. Repligen Corp’s trailing 12-month revenue is $669.8 million with a 17.3% net profit margin. Year-over-year quarterly sales growth most recently was -29.6%. Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 22.25% in the past year. Currently, Repligen Corp’s price-earnings ratio is 66.4. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.Currently, there are 55.71 million shares of Repligen Corp stock available for purchase. Repligen Corp’s price-earnings (P/E) ratio is currently at 65.7, which is high compared to the Medical Equipment, Supplies & Distribution industry median of 37.9. The price-earnings ratio gauges market expectation of future performance by relating a stock ...Repligen Corp (RGEN) will release its next earnings report on Feb 15, 2024. In the last quarter Repligen Corp reported $0.165 EPS in relation to $0.23 expected by the market. ... Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the ...Listed in 1986. repligen corporation is a life sciences company focused on the development, production and commercialization of products used in the process ...On September 5, 2023, Repligen Corporation (NASDAQ:RGEN) stock closed at $169.41 per share. One-month return of Repligen Corporation (NASDAQ:RGEN) was -1.99%, and its shares lost 23.82% of their ...Financial Details for the Fourth Quarter and Full Year 2021. Total revenue for the fourth quarter of 2021 increased to $186.5 million compared to $108.6 million for the fourth quarter of 2020, a year-over-year gain of 72% as reported and 73% at constant currency, with organic growth of 69%. Total revenue for the full year 2021 increased to …
When starting a business, one of the most important decisions you’ll have to make is choosing the right legal structure. Limited Liability Companies (LLCs) and S Corporations (S Corps) are two popular options that offer liability protection...
What is Repligen Corp (RGEN)'s stock price today? The current price of RGEN is $153.28. The 52 week high of RGEN is $212.17 and 52 week low is $110.45. When is next earnings date of Repligen Corp (RGEN)? The next earnings date of Repligen Corp (RGEN) is …Repligen Corp’s ( RGEN) price is currently down 11.17% so far this month. During the month of April, Repligen Corp’s stock price has reached a high of $182.42 and a low of $149.02. Over the last year, Repligen Corp has hit prices as high as $262.26 and as low as $137.21. Year to date, Repligen Corp’s stock is down 43.53%.Nov 30, 2023 · The latest Repligen stock prices, stock quotes, news, and RGEN history to help you invest and trade smarter. A vertical stack of three evenly spaced horizontal lines. ... Repligen Corp. is a ... Dec 1, 2023 · View Repligen Corporation RGEN investment & stock information. Get the latest Repligen Corporation RGEN detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 15.54% in the past year. Currently, Repligen Corp’s price-earnings ratio is 72.6. Repligen Corp’s trailing 12-month revenue is $669.8 million with a 17.3% net profit margin. Year-over-year quarterly sales growth most recently was -29.6%.Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 30.36% in the past year. Currently, Repligen Corp’s price-earnings ratio is 58.9. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.
Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 14.71% in the past year. Currently, Repligen Corp’s price-earnings ratio is 47.0. Repligen Corp’s trailing 12-month revenue is $777.8 million with a 21.6% net profit margin. Year-over-year quarterly sales growth most recently was -11.5%.
Repligen Corp stock has a Growth Score of 82, Momentum Score of 48 and Quality Score of 71. Comparing Baxter International Inc and Repligen Corp’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not.
Stock RGEN November 29, 2023 NASDAQ 20 minutes delay $160.44 3.54 (2.256%) Open 157.9 ... Repligen Corporation | 28,921 followers on LinkedIn. FRAUD ALERT: Please take note that it has come to our ...To be eligible to participate in a Job Corps program, applicants must qualify for low-income status under one of five income-related standards: cash assistance, food assistance, earned income, foster child and homelessness.The Short Squeeze Score is the result of a sophisticated, multi-factor quantitative model that identifies companies that have the highest risk of experiencing a short squeeze. The scoring model uses a combination of short interest, float, short borrow fee rates, and other metrics. The number ranges from 0 to 100, with higher numbers indicating ...45.97M. 305.46%. Get the latest Repligen Corp (RGEN) real-time quote, historical performance, charts, and other financial information to help you make more informed …Reports first quarter revenue of $182.7 million, with base business growth of 4% as reported and 7% at constant currency Reports first quarter gross margin of 55.2% on both GAAP and adjusted (non-GAAP) basis Closed on acquisition of single-use bag manufacturer FlexBiosys Inc. in April WALTHAM, Mass., May 02, 2023 (GLOBE …Repligen Corp stock has a Value Score of 5, Momentum Score of 54 and Estimate Revisions Score of 37. Comparing Agiliti Inc and Repligen Corp’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk ...Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 22.25% in the past year. Currently, Repligen Corp’s price-earnings ratio is 66.4. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.www .repligen .com. Repligen is an American company devoted to the development and production of materials used in the manufacture of biological drugs. 2014 The company is based in Waltham, Massachusetts, 2014 and incorporated in Delaware in 1981. [1] A public company, Repligen is listed on the NASDAQ exchange under the symbol RGEN. [2]Dec 4, 2023 · Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 7.77% in the past year. Currently, Repligen Corp’s price-earnings ratio is 81.2. Repligen Corp’s trailing 12-month revenue is $669.8 million with a 17.3% net profit margin. Year-over-year quarterly sales growth most recently was -29.6%. Dec 4, 2023 · Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 7.77% in the past year. Currently, Repligen Corp’s price-earnings ratio is 81.2. Repligen Corp’s trailing 12-month revenue is $669.8 million with a 17.3% net profit margin. Year-over-year quarterly sales growth most recently was -29.6%. Get the latest Repligen Corporation (RGEN) stock news and headlines to help you in your trading and investing decisions.
Repligen Corp’s Stock Price as of Market Close. As of April 28, 2023, 4:00 PM CST, Repligen Corp’s stock price was $151.63. Repligen Corp is up 4.46% from its previous closing price of $145.15. During the last market session, Repligen Corp’s stock traded between $144.20 and $149.36.Stock RGEN November 29, 2023 NASDAQ 20 minutes delay $160.44 3.54 (2.256%) Open 157.9 ... Repligen Corporation | 28,921 followers on LinkedIn. FRAUD ALERT: Please take note that it has come to our ...Repligen Corp stock has a Momentum Score of 57, Estimate Revisions Score of 50 and Quality Score of 73. Comparing DexCom, Inc. and Repligen Corp’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as …Instagram:https://instagram. forex brokers listjacksonfinancialbest cryptocurrency irainsider trades Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 15.54% in the past year. Currently, Repligen Corp’s price-earnings ratio is 72.6. Repligen Corp’s trailing 12-month revenue is $669.8 million with a 17.3% net profit margin. Year-over-year quarterly sales growth most recently was -29.6%. setting up a real estate investment fundjewelers mutual vs lavalier Currently, there are 55.54 million shares of Repligen Corp stock available for purchase. Repligen Corp’s price-earnings (P/E) ratio is currently at 49.4, which is high compared to the Medical Equipment, Supplies & Distribution industry median of 33.1. The price-earnings ratio gauges market expectation of future performance by relating a stock ...On September 12, 2023, Repligen Corp (HONE) stock performed well, with a median target price forecast of $200.00. The consensus among the 13 polled investment analysts is to buy stock in Repligen Corp. Repligen Corp is expected to release its current quarter earnings report on October 26. The company is projected to have earnings per share of ... zim stock news Repligen Corp. (NASDAQ:RGEN) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in ...Fundamentals REPLIGEN CORP. DL-,01. Dividend. Dividend yield in %. P/E Ratio. Profit per share. Number of shares. Market capitalization. News about REPLIGEN ...The Growth Grade Winner: Repligen Corp. As you can clearly see from the Growth Grade breakdown above, Repligen Corp has a more attractive growth grade than Medtronic PLC. For investors who focus solely on how a company is growing relative to other companies in the same industry, Repligen Corp could be a good stock to add to their portfolio.